Market capitalization | $20.49m |
Enterprise Value | $-27.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.39 |
EV/Sales (TTM) EV/Sales | -2.52 |
P/S ratio (TTM) P/S ratio | 1.86 |
P/B ratio (TTM) P/B ratio | 1.44 |
Revenue (TTM) Revenue | $11.00m |
EBIT (operating result TTM) EBIT | $-73.94m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
4 Analysts have issued a BioAtla Inc forecast:
4 Analysts have issued a BioAtla Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 11 11 |
-
|
|
Gross Profit | 10 10 |
926%
926%
|
|
EBITDA | -73 -73 |
43%
43%
|
EBIT (Operating Income) EBIT | -74 -74 |
43%
43%
|
Net Profit | -70 -70 |
43%
43%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Jay Short |
Employees | 76 |
Founded | 2007 |
Website | www.BioAtla.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.